Liver Fibrosis Model
Why Liver Fibrosis Models Matter
Compared with rodent systems, human liver fibrosis is profoundly influenced by metabolic status, immune regulation, and liver architecture. Differences in disease progression kinetics, fibrosis patterns, and drug metabolism between small animals and humans often lead to a translational disconnect-where compounds demonstrate efficacy in animals but fail to translate clinically.
Non-human primate (NHP) models, owing to their close similarity to humans in hepatic physiology, immune responses, and metabolic pathways, are increasingly recognized as a critical bridge for improving the clinical predictability of antifibrotic drug development.
Prisys Biotech's Strategy for Cynomolgus Monkey Liver Fibrosis Models
Driven by translational medicine needs, Prisys Biotech has established a cynomolgus monkey liver fibrosis model platform designed to systematically reproduce disease evolution rather than focusing on isolated endpoints.
The model is developed on a metabolic dysfunction–associated steatotic liver disease (MASLD) background, with progression to metabolic dysfunction–associated steatohepatitis (MASH, formerly known as NASH). Through sustained metabolic stress combined with hepatic injury, the model recapitulates a continuous pathological spectrum-from steatosis and inflammation to progressive fibrotic deposition.
Key considerations in model design include:
- Whether disease evolution follows clinically recognized pathological sequences
- Whether fibrosis progression is stage-dependent and longitudinally traceable
- Whether inter-individual variability can be objectively assessed and stratified
This strategy enables the model to support studies across multiple R&D stages, including fibrosis initiation, progression, and potential regression.
A Multimodal and Quantitative Evaluation Framework
High-quality disease models must be supported by robust and reliable assessment systems. Prisys Biotech has established a multimodal evaluation framework integrating imaging, circulating biomarkers, and histopathology:
-
Imaging-Based Assessment
Clinically translatable, non-invasive imaging technologies are applied for longitudinal monitoring of liver stiffness and steatosis, providing quantitative readouts for disease progression and treatment response.
-
Serum and Molecular Biomarkers
Comprehensive monitoring of liver function, metabolic parameters, and fibrosis- and inflammation-related biomarkers supports pharmacodynamic evaluation, mechanism-of-action studies, and biomarker discovery.
-
Histopathological Confirmation
Liver tissue samples collected at predefined time points are analyzed using classical staining methods and internationally recognized scoring systems. Histopathology serves as the reference standard for confirming fibrosis severity and therapeutic efficacy.
Cross-validation across these data layers minimizes bias associated with single-endpoint interpretations.
Demonstrated Performance in Translational Studies
In prior antifibrotic research programs, Prisys Biotech's cynomolgus monkey liver fibrosis model has been successfully applied to pharmacodynamic evaluations of candidate compounds. Through structured workflows-including model induction, animal stratification, sustained dosing, and multi-endpoint analysis-the platform enables integrated assessment of therapeutic effects at imaging, molecular, and histological levels.
These studies have demonstrated the model's stability, reproducibility, and internal data consistency, supporting its suitability for translational decision-making.
A Translational Research Platform, Not a Standalone Model
Prisys Biotech's cynomolgus monkey liver fibrosis capability represents a translational research platform, offering:
Disease phenotypes closely aligned with clinical reality
- Support for diverse mechanisms of action and therapeutic strategies
- Applicability to pharmacodynamics and biomarker exploration
- Flexibility for study design customization based on project needs
Cholestasis-Driven Liver Fibrosis Model (BDS Mechanism)
In addition to metabolic liver fibrosis models, Prisys Biotech has established a cholestasis-driven cynomolgus monkey liver fibrosis model, designed to mimic fibrosis driven primarily by impaired bile flow.
By applying controlled modulation of biliary drainage-without complete bile duct obstruction-the model induces sustained intrahepatic cholestasis, followed by hepatocellular injury, inflammation, and progressive fibrotic remodeling. Compared with complete bile duct ligation models, this approach offers improved disease stability and long-term animal survival, making it particularly suitable for mid- to long-term pharmacodynamic studies.
Throughout model establishment and maintenance, liver function parameters are regularly monitored, and liver tissue is collected at key time points for systematic histopathological evaluation, enabling dynamic assessment of cholestasis severity and fibrosis progression.
This model serves as an important complement to metabolic liver fibrosis models, expanding the translational toolkit for antifibrotic drug evaluation across distinct etiological mechanisms.
Conclusion
The central challenge in antifibrotic drug development is not the absence of models, but whether those models can meaningfully inform clinical decision-making. Through its non-human primate liver fibrosis research platform, Prisys Biotech aims to help development teams identify candidates with genuine translational potential earlier in the preclinical phase.
For further discussion on model applicability or study design strategies, we welcome professional scientific exchange.
Related capabilities. This model is commonly combined with ADME services, clinical imaging and biodistribution imaging within an integrated NHP study.
Hot Tags: liver fibrosis model, research, study, monkey, gene therapy, nhp company, Neuropathic Pain Nonhuman Primates Disease Model, peptide PD pharmacology, Inflammatory Bowel Disease Nonhuman Primates, drug PD pharmacology, RNA PK pharmacology
You Might Also Like
Send Inquiry
